Myeloproliferative Neoplasms section

Myeloproliferative Neoplasms News & Features

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.

First Case of Dermatomyositis Associated with Secondary Myelofibrosis Following Polycythemia Vera

First Case of Dermatomyositis Associated with Secondary Myelofibrosis Following Polycythemia Vera

A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.

Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML

Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML

A chart review reveals 3 cases of CML developing in patients with diagnoses of ET and PV.

Impact of ET Treatments on Secondary Malignancies Not Statistically Significant

Impact of ET Treatments on Secondary Malignancies Not Statistically Significant

Treatments for essential thrombocythemia (ET) comprising hydroxyurea and alkylating agents did not appear to impact development of secondary malignancies in patients with ET.

Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers

Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers

A lack of needed transfusion services was cited as why many hematologic oncologists are less likely to refer their patients with blood cancers to home hospice care.

JAK2 Mutation, Leukocytosis Are Predictive Factors of Thrombosis in Essential Thrombocythemia

JAK2 Mutation, Leukocytosis Are Predictive Factors of Thrombosis in Essential Thrombocythemia

Presence of JAK2 mutation and leukocytosis are strong predictors for thromboembolic events in patients with essential thrombocythemia (ET).

Improving Outcomes with Clinical Practice Guidelines for Myeloproliferative Neoplasms

Improving Outcomes with Clinical Practice Guidelines for Myeloproliferative Neoplasms

NCCN released its newest Clinical Practice Guidelines in Oncology. These guidelines will assist with preventive, diagnostic, and treatment decisions for patients with myelofibrosis, as well as the other myeloproliferative neoplasms, essential thrombocythemia and PV.

New Predisposition Genes for Familial Polycythemia Vera Are Identified

New Predisposition Genes for Familial Polycythemia Vera Are Identified

Predisposition genes for familial polycythemia vera were identified via exome sequencing in a Finnish family with 4 patients.

JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed

JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed

Myelofibrosis, extensive splenomegaly, and symptomatic burden are significantly improved for patients with MPN by JAK1 and JAK2 inhibition; however, some major needs in this patient group are still largely unmet.

Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)

Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)

This fact sheet examines the various kinds of chronic myeloproliferative neoplasms, and the tests utilized to detect and diagnose them.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs